Glucotrack Unveils Revolutionary Continuous Blood Glucose Monitor Technology at Upcoming Webinar
Glucotrack is set to showcase its innovative Continuous Blood Glucose Monitor (CBGM) technology, offering a potential breakthrough in diabetes management with longer-lasting, real-time monitoring capabilities.
Medical technology company Glucotrack will host a virtual webinar to demonstrate its innovative Continuous Blood Glucose Monitor (CBGM) technology, presenting a potential paradigm shift in diabetes management. The event, scheduled for May 29, will highlight the company's unique approach to monitoring blood glucose levels with an implantable device that promises more accurate and prolonged tracking.
Current diabetes management tools often require frequent finger pricks and provide limited insights. Glucotrack's CBGM technology offers a significant improvement by providing real-time glucose readings directly from the bloodstream, eliminating the lag time associated with traditional subcutaneous sensors.
A key differentiator of Glucotrack's technology is its extended usability. While many continuous glucose monitors require sensor replacement every ten to 90 days, the company's implantable device can function for two to three years. A recent preclinical study demonstrated a Mean Absolute Relative Difference of 4.7% at 90 days, indicating high accuracy in glucose monitoring.
The webinar comes at a critical time, with diabetes projected to impact 643 million people globally by 2030, rising to 783 million by 2045. Glucotrack's technology could potentially transform diabetes management by providing patients with more comprehensive, less invasive monitoring options.
During the event, company experts will discuss the technology's mechanics, share clinical trial updates, and participate in a live Q&A session. The webinar represents an opportunity for healthcare professionals, patients, and technology enthusiasts to gain insights into an emerging solution for diabetes management.